ROP — Roper Technologies, Inc.

The sell-side is split rather than hostile: 14 Buy/Strong Buy vs 6 Hold and 3 Sell, consensus target $427.71 (recent average $436.83), with a $355 low and $526 high. Sentiment improved through the summer on the July 23, 2026 Q2 beat and the raised FY26 adjusted DEPS guide of $22.15-$22.30, plus 9.0M shares repurchased for $3.2B over the prior three quarters (a $1.2B/3.6M-share chunk in Q2 alone) that rolled the share count back to 2013 levels. But the tape has cooled into mid-September 2026 - RSI 41.49, price 4.72% below its 20-day average, -4.61% in the past week - because the debate is unresolved: the market will not pay a 25x forward multiple for 5% organic growth and a balance sheet where long-term debt has gone from $6.46B (Q1 2025) to $10.60B (Q2 2026) to fund buybacks and M&A.

Revenue has grown every quarter for three years, from $1.563B (Q3 2023) to $2.109B (Q2 2026), but the growth rate is decelerating, not accelerating: YoY revenue growth went 7.5% (Q1 2024) to 16.3% (Q4 2024) to 14.3% (Q3 2025) to 11.3% (Q1 2026) and down to 8.5% (Q2 2026), with sequential growth fading to +1.8% and then +0.6% in the last two quarters. Organic growth is only ~5% per the July 23, 2026 release - the rest is acquired. Gross margin is steady and high at 69.7% in Q2 2026 (vs 70.3% in Q1 2024), but GAAP operating margin has compressed from 28.7% in Q4 2023 / 28.8% in Q2 2024 to 27.2% (Q1 2026) and 27.7% (Q2 2026), consistent with rising acquired-intangible amortization layered on top of acquisitions. GAAP EPS is not usable as a trend line: Q2 2026 net income of $1.1685B and EPS of $11.48 dwarf the prior three quarters (Q1 2026 $4.87, Q4 2025 $3.97, Q3 2025 $3.68) because of a non-operating gain, and FY2025 GAAP EPS of ~$14.20 was actually slightly below FY2024's ~$14.34. The cleaner signal is cash and adjusted earnings: TTM operating cash flow of $2.669B is up 10.7% YoY, H1 2026 free cash flow of $1.036B is up 14% YoY, and adjusted diluted EPS grew 10% to $5.38 in Q2 2026. Verdict: a decelerating but still-growing, high-margin cash compounder whose reported GAAP lines are noisy and whose margin structure is being diluted by the M&A engine.

Modestly cheap versus its own history, but the discount is partly earned. As of 2026-09-13, the stock trades at 17.49x the FY2026 adjusted EPS estimate of $22.218 and at 15.9x a plausible FY2027 number of ~$24.4 (+10%), against a 5-year average P/E of 39.07 and 5-year average P/S of 8.52 versus the current 4.735. The reported TTM P/E of 16.11 and PEG of 0.237 should be thrown out - both are distorted by the Q2 2026 one-off gain in the $24.48 TTM EPS and by FY2025 GAAP EPS being flattered in the prior-year base by divestiture gains. The fair comparison is 17.5x forward adjusted earnings for a business with a 69.5% gross margin, 27-28% operating margin, ~$2.6-2.8B of annual free cash flow (6.7% TTM FCF yield) and a 1.0% dividend yield - that is cheap for a 10% adjusted-EPS compounder, but not absurdly cheap once you net the 3.4x net debt/EBITDA and 5% organic growth. Price/book of 2.13 and EV/EBITDA of ~11.3x on the screener's calculation also screen cheap in absolute terms. I would call this fair-to-cheap with a clear value tilt, not a bargain.

The stock at $388.52 is not paying you for the guidance raise that already happened on July 23, 2026 - it sits ~10% below the $427.71 consensus target and ~11% below my own fair value; the market is withholding multiple expansion until it sees organic growth re-accelerate above 5% and evidence that the $5B+ M&A pipeline can be deployed accretively rather than just defensively. The setup is asymmetric in the near term: consensus Q3 2026 EPS is ~$5.79 (report ~Oct 22-23, 2026), and holding the $22.15-$22.30 full-year guide through that print would put the stock on ~17x forward with a 6.7% trailing FCF yield - a level that historically has not persisted for Roper outside of broad market dislocations, despite beta of only 0.747. The bear read is equally concrete: if organic growth slips below 5% and the company has to lever up further to hit the $5B deployment target, the multiple stays where it is and FY2027 EPS growth compresses below 10%, in which case 15-16x forward is the right anchor and $388 is fair, not cheap. Watch the H2 2026 free cash flow conversion and any new long-term debt issuance as the tell for which path is playing out.

As of 2026-09-13, RSI(14) stood at 41.49 - soft and drifting lower, but nowhere near oversold, so there is room to fall to the low 30s before a mean-reversion bid shows up. Price was 4.72% below its 20-day SMA (~$407.77), a hair above its 50-day SMA (~$388.02 at +0.13%), and 3.59% above its 200-day SMA (~$375.05). The return profile confirms a pullback inside an uptrend rather than a breakdown: -4.61% over 1 week and -1.70% over 1 month, but +15.99% over 3 months and +10.69% over 6 months. Entry-timing implication: the 50-day line at roughly $388 is being tested right now and is the first real decision point; the 200-day near $375 is the more meaningful accumulation zone, and I would want to see RSI stabilize above ~40 while price holds the 50-day before treating this as a completed dip rather than the start of a deeper retracement toward $360-375.

• Rate path and refinancing cost: long-term debt rose from $6.46B (Q1 2025) to $10.60B (Q2 2026), lifting debt/equity to 0.605 and net debt/EBITDA to roughly 3.4x - every incremental quarter of high rates raises the hurdle on the $5B+ M&A program.
• Defensive software rotation: with high recurring revenue, a 69.5% gross margin and a 6.7% trailing FCF yield, Roper is a natural landing spot when investors rotate out of more cyclical or higher-beta technology, which is a steady floor under the multiple.
• Freight and government end markets: DAT's load-matching volumes and Deltek's GovCon exposure are the two genuinely cyclical pockets flagged in the research brief, and any federal budget or freight-rate softness shows up directly in organic growth.
• Private software M&A pricing and credit availability: management's ability to deploy $5B+ at cash-accretive prices over the next 12-18 months depends on private valuations and the cost of acquisition debt, both outside the company's control.
• Cohort-wide multiple compression in application software: Roper's de-rating from the mid-20s/low-30s forward P/E it commanded historically to ~17.5x is a sector-level event as much as a company-level one, and it can persist even while fundamentals hold.
• Capital-light cost structure as a hedge: capex was only $11.0M in Q2 2026 on $2.109B of revenue (0.5% of sales), so there is no supply-chain or capital-intensity exposure to hedge against.

• Q3 2026 earnings, tentatively October 22-23, 2026, with consensus EPS of ~$5.79 - the first real test of whether the raised FY2026 adjusted DEPS guidance of $22.15-$22.30 survives contact with H2 organic growth.
• Announcement of a large acquisition from the $5B+ deployment pipeline - a well-priced, cash-accretive deal would validate the capital-allocation story and likely re-rate the multiple; an expensive or debt-funded one would do the opposite.
• Continued share repurchase: 9.0M shares for $3.2B were bought over the three quarters into mid-2026, cutting the count to ~100.9M shares and rolling it back to 2013 levels, which mechanically supports adjusted EPS growth.
• Monetization of agentic AI workflow features across Deltek, Vertifor and DAT, which management has framed as an addressable-market expander and a driver of deeper customer lock-in rather than a cost item.
• Any stabilization or recovery in freight matching and government contracting volumes, the two end markets most likely to swing organic growth from ~5% back toward the mid-single-digit-plus range.

• Organic growth is stuck at ~5% and total revenue growth has decelerated for four straight quarters from 16.3% YoY (Q4 2024) to 8.5% (Q2 2026) - the compounding now depends on acquisitions, not the core.
• Balance-sheet leverage: long-term debt is up 64% in five quarters to $10.60B, current ratio is 0.553 and quick ratio 0.511, and stockholders' equity fell from $19.88B (Dec 2025) to $18.70B (Jun 2026) because $3.2B of buybacks were funded while debt rose - a debt-funded-buyback pattern that limits flexibility if rates stay high.
• Earnings quality and one-off distortion: the TTM P/E of 16.11 and PEG of 0.237 are both flattered by the Q2 2026 gain embedded in the $11.48 GAAP EPS, and the deterministic score's accruals ratio of +1.99% as of 2026-06-30 shows reported net income running modestly ahead of operating cash flow.
• GAAP operating margin has compressed from 28.7-28.8% in 2024 to 27.2-27.7% in H1 2026, and reported ROIC of 5.6% and ROE of 7.7% are depressed by goodwill from two decades of acquisitions - the return on each incremental deal is not obviously improving.
• Wide analyst dispersion with three Sell ratings and a $355 low target - the bear case is not fringe, it is that a 5%-organic-growth, 3.4x-levered serial acquirer deserves a mid-teens forward multiple, not a premium one.

Roper is a genuinely good business trading at a real discount to its own history, but this is not a table-pounding buy at $388.52. On the positives: 69.7% gross margins, ~$2.6-2.8B of annual free cash flow (6.7% TTM yield), capex at 0.5% of sales, a 1.0% dividend, beta of 0.747, TTM operating cash flow up 10.7% YoY, adjusted EPS up 10% in Q2 2026, a raised FY2026 guide of $22.15-$22.30, and a 17.5x forward adjusted P/E against a 39.07 five-year average. On the negatives: organic growth is only 5% and total revenue growth has slid from 16.3% to 8.5% YoY in four quarters, GAAP operating margin is down roughly 100bp, long-term debt is up 64% to $10.60B, and the compounding now requires $5B+ of acquisitions rather than organic reinvestment - which is exactly why a low-ROIC, goodwill-heavy serial acquirer should not get its old multiple back. My read is that fair value is around $432, so the stock is roughly 11% cheap with the October 22-23 print as the swing factor; I would rather accumulate on a test of the 200-day near $375 than chase here, and I would want to see organic growth stabilize above 5% and debt stop climbing before treating this as a full position.

Calculated as a 60/40 blend of two approaches applied to FY2026 estimates: (a) 19.5x forward adjusted EPS of $22.218 - a multiple that reflects a partial re-rating from the current ~17.5x toward Roper's pre-de-rating norm but discounts for 5% organic growth, 3.4x net debt/EBITDA and rising acquired-amortization drag - giving $433 per share; and (b) a 6.4% required free-cash-flow yield on FY2026E free cash flow of ~$2.78B (H1 2026 actual FCF of $1.036B annualized with normal H2 seasonality), giving a $43.4B market cap or ~$430 on 100.9M shares. The weighted blend lands at ~$432, roughly 11% above the 2026-09-13 price of $388.52 and modestly below the $436.83 recent-average analyst target.